- Home
- RLYB vs BOLD Comparison
RLYB vs BOLD Comparison
Compare RLYB & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLYB | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 25.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RLYB | BOLD |
|---|---|---|
| Price | $9.75 | $1.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 243.4K | 57.8K |
| Earning Date | 05-07-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.22 | $0.96 |
| 52 Week High | $11.49 | $1.78 |
Technical Indicators
Market Signals| Indicator | RLYB | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 71.74 | 54.72 |
| Support Level | $0.48 | $1.15 |
| Resistance Level | $11.49 | $1.19 |
| Average True Range (ATR) | 0.91 | 0.03 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 61.49 | 87.50 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.